![Quest Expands into MRD Liquid Biopsy with Haystack Oncology Buy](https://www.g2intelligence.com/wp-content/uploads/2023/05/May10-2023.News_.CLIAStaffingQuestLiquidBiopsyBuy-iStock-1405940919-1100x800-1-1080x675.jpg)
Quest Expands into MRD Liquid Biopsy with Haystack Oncology Buy
The acquisition of the Johns Hopkins spin out and its liquid biopsy ctDNA test will significantly strengthen Quest’s oncology offerings.
The acquisition of the Johns Hopkins spin out and its liquid biopsy ctDNA test will significantly strengthen Quest’s oncology offerings.
In terms of Medicare coverage, 2023 is shaping up to be a fruitful year—here are five of the most significant approvals so far.
New document aims to help clinicians navigate screening guidelines, choose testing strategies, and analyze test results.
A new OIG Advisory Opinion sheds some light on when it’s permissible for a lab to offer customers a gift card for returning their at-home testing kit.
On Friday, the US federal trade commission ordered Illumina to divest Grail, which it acquired for $8 billion in August 2021.